Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MabVax Therapeutics Holdings Inc.

www.mabvax.com

Latest From Flexus Biosciences Inc.

Scrip's Rough Guide To IDO

IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.

ImmunoOncology Research & Development

Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities

Opdivo first-quarter sales were still strong at $1.1bn, largely driven by lung cancer use and helping to drive overall performance, but potential approval of Merck's competing Keytruda with chemotherapy in first-line lung cancer is right around the corner.

ImmunoOncology Cancer

IDO Emerges As Clean Combo Partner, Rising Star At AACR

Clean safety profile for combination of IDO inhibitors with anti-PD-1 agents in early studies presented at the American Association for Cancer Research meeting contrasts with the toxicity-laden CTLA-4/PD-1 regimen in Bristol's Phase III CheckMate 067 study.

ImmunoOncology Clinical Trials

Immuno-Oncology 2.0 Roundtable: Emerging Players Eye Crowded Field

Scrip spoke with five companies about their places in the crowded IO field in which big pharma and small biotech firms alike are seeking the best options for harnessing the immune system to fight cancer.

ImmunoOncology Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Alias(es)
  • Terrapin Diagnostics Inc.
  • Telik Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • MabVax Therapeutics Holdings Inc.
  • Senior Management
  • J. David Hansen, Pres. & CEO
    Gregory P Hanson, CFO
    Philip Livingston, MD, CSO
    Paul Resnick, MD, VP, CBO
  • Contact Info
  • MabVax Therapeutics Holdings Inc.
    Phone: (858) 259-9405
    11535 Sorrento Valley Rd.
    Ste. 400
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register